Business Model Breakdown
How Omada Health Inc Makes Money
OMDA
Market Cap
$901M
Profit Margin
-4.9%
The Short Version
Omada Health provides a comprehensive digital platform designed to help individuals manage and prevent chronic conditions such as diabetes, hypertension, and behavioral health issues. The company partners primarily with large employers and health plans, offering personalized, evidence-based programs that combine digital tools, expert coaching, and peer support. Revenue is generated through these enterprise contracts, typically based on a per-member-per-month (PMPM) fee or value-based agreements tied to health outcomes, aiming to reduce long-term healthcare costs for its clients.
Where the Revenue Comes From
Subscription/service fees from employers and health plans (approx. 100% of revenue)
Who buys: Employers, health plans, and their covered members.
Why It Works (Competitive Advantages)
- ✔Strong gross margins (72.6%) indicating efficient service delivery.
- ✔Proven platform for chronic disease management achieving GAAP profitability.
- ✔Established partnerships within employer and health plan ecosystems.
Economic Moat: Narrow (Switching Costs (patient engagement, data integration with health systems), Intangible Assets/IP (proprietary clinical protocols, data-driven insights))
What Our Analysis Says
DVR Score as of May 4, 2026
Score Change Explanation: The previous analysis on 2026-03-13 assigned a score of 0.1/10 (1/100) because Omada Health Inc. was identified as a privately held company, making an analysis based on public stock metrics invalid. The current analysis, dated 2026-05-04, is based on extensive real-time market intelligence that confirms Omada Health Inc. (OMDA) is now publicly traded. This fundamental change in the company's trading status necessitates a complete re-evaluation of its investment potential as a public stock. Omada Health (OMDA) shows promising 10x potential within 3-5 years, driven by its 58% YoY revenue growth and recent achievement of GAAP profitability (Q4 2025). Operating in the high-growth digital chronic care management market, its 72.6% gross margin is strong. Institutional interest is positive, with significant inflows. However, the path to sustained profitability is not yet fully established, indicated by a projected negative EPS for Q1 2026. Competitive intensity from larger players like Hinge Health and insider selling activity represent notable risks. While the company is making strong strides, a clear, expanding competitive moat needs further demonstration to solidify its long-term market leadership and justify maximal 10x confidence. Financial health details are also somewhat limited from the provided snapshot, necessitating a cautious but optimistic assessment.